tiprankstipranks
Trending News
More News >

Calliditas announces partner approval, EUR 10M milestone payment

Calliditas Therapeutics announced that the European Commission has granted a full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy. The European Commission has granted a full marketing authorization of Kinpeygo. Kinpeygo is marketed in in the European Union and UK exclusively by Calliditas’ commercial partner, Stada Arzneimittel. This approval triggers a milestone payment of EUR 10M to Calliditas, which will be recognized as revenue in Q3.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1